Wendy Stock to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications Wendy Stock has written about Histone Deacetylase Inhibitors.
Connection Strength
0.813
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.471
-
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101.
Score: 0.309
-
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.
Score: 0.034